[go: up one dir, main page]

CR20120027A - Polipeptidos y metodo de tratamiento - Google Patents

Polipeptidos y metodo de tratamiento

Info

Publication number
CR20120027A
CR20120027A CR20120027A CR20120027A CR20120027A CR 20120027 A CR20120027 A CR 20120027A CR 20120027 A CR20120027 A CR 20120027A CR 20120027 A CR20120027 A CR 20120027A CR 20120027 A CR20120027 A CR 20120027A
Authority
CR
Costa Rica
Prior art keywords
antigen
polypeptides
treatment method
binding
binding proteins
Prior art date
Application number
CR20120027A
Other languages
English (en)
Inventor
Michael Neil Burden
Paul Andrew Hamblin
Jonathan David Larkin
John Richard White
Original Assignee
Fexco Merchant Services
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fexco Merchant Services, Glaxo Group Ltd filed Critical Fexco Merchant Services
Publication of CR20120027A publication Critical patent/CR20120027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)

Abstract

Se proporciona en la presente memoria una proteína de unión a antígeno aislada que comprende al menos un primer dominio variable de inmunoglobulina capaz de unirse a la ADAMTS5 humana. También se proporcionan proteínas de unión a antígeno de la presente invención que son anticuerpos monoclonales, composiciones farmacéuticas que comprenden dichas proteínas de unión a antígeno y métodos de tratamiento.
CR20120027A 2009-07-02 2012-01-16 Polipeptidos y metodo de tratamiento CR20120027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22252109P 2009-07-02 2009-07-02
US24975709P 2009-10-08 2009-10-08

Publications (1)

Publication Number Publication Date
CR20120027A true CR20120027A (es) 2012-05-16

Family

ID=43411744

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120027A CR20120027A (es) 2009-07-02 2012-01-16 Polipeptidos y metodo de tratamiento

Country Status (21)

Country Link
US (1) US20120095193A1 (es)
EP (1) EP2449127A4 (es)
JP (1) JP2012531902A (es)
KR (1) KR20120098587A (es)
CN (1) CN102482700A (es)
AR (1) AR077630A1 (es)
AU (1) AU2010266272A1 (es)
BR (1) BR112012000025A2 (es)
CA (1) CA2766641A1 (es)
CL (1) CL2011003354A1 (es)
CO (1) CO6480976A2 (es)
CR (1) CR20120027A (es)
DO (1) DOP2011000404A (es)
IL (1) IL217292A0 (es)
MA (1) MA33387B1 (es)
MX (1) MX2012000055A (es)
PE (1) PE20120554A1 (es)
SG (1) SG177288A1 (es)
TW (1) TW201114436A (es)
UY (1) UY32752A (es)
WO (1) WO2011002968A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US20130336989A1 (en) * 2011-02-24 2013-12-19 Glaxo Group Limited Methods of identifying a patient population
WO2013109829A1 (en) * 2012-01-20 2013-07-25 Glaxosmithkline Intellectual Property Development Ltd Anti-adamts4 antibodies and methods of treatment
PL2650310T3 (pl) * 2012-04-13 2017-01-31 Rottapharm Biotech S.R.L. Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania
WO2015056808A1 (en) * 2013-10-15 2015-04-23 Genefrontier Corporation Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
WO2017019729A1 (en) * 2015-07-27 2017-02-02 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
CA3064469A1 (en) * 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
AU2018277310B2 (en) * 2017-06-02 2024-07-11 Ablynx Nv Aggrecan binding immunoglobulins
EP3630817A1 (en) * 2017-06-02 2020-04-08 Merck Patent GmbH Polypeptides binding adamts5, mmp13 and aggrecan
KR20250011229A (ko) 2017-06-02 2025-01-21 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
CA3081823A1 (en) * 2017-11-09 2019-05-16 Ribomic Inc. Aptamer for adamts5 and use for aptamer for adamts5
CN110760483B (zh) * 2019-11-08 2021-06-22 扬州大学 具牛、羊交叉反应的抗TNF-α单克隆抗体的制备及应用
WO2021154534A1 (en) * 2020-01-28 2021-08-05 Promab Biotechnologies, Inc. Plap-cd3 epsilon bispecific antibodies
WO2024054922A1 (en) * 2022-09-07 2024-03-14 Synoa Therapeutics, Llc Methods and compositions comprising novel bispecific antibodies
CN119775410B (zh) * 2025-03-11 2025-04-29 成都大熊猫繁育研究基地 一种抗大熊猫vegfa单克隆抗体、杂交瘤细胞株及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391610B1 (en) * 1999-08-06 2002-05-21 The Cleveland Clinic Foundation Nucleic acids encoding zinc metalloproteases
WO2005061459A1 (en) * 2003-12-04 2005-07-07 Wyeth Biaryl sulfonamides and methods for using same

Also Published As

Publication number Publication date
SG177288A1 (en) 2012-02-28
JP2012531902A (ja) 2012-12-13
MA33387B1 (fr) 2012-06-01
TW201114436A (en) 2011-05-01
PE20120554A1 (es) 2012-06-08
KR20120098587A (ko) 2012-09-05
CL2011003354A1 (es) 2012-07-20
EP2449127A4 (en) 2013-01-16
CO6480976A2 (es) 2012-07-16
US20120095193A1 (en) 2012-04-19
AU2010266272A1 (en) 2012-01-19
DOP2011000404A (es) 2012-04-15
WO2011002968A3 (en) 2011-04-07
IL217292A0 (en) 2012-02-29
CN102482700A (zh) 2012-05-30
CA2766641A1 (en) 2011-01-06
UY32752A (es) 2011-01-31
MX2012000055A (es) 2012-01-27
WO2011002968A2 (en) 2011-01-06
EP2449127A2 (en) 2012-05-09
BR112012000025A2 (pt) 2015-09-08
AR077630A1 (es) 2011-09-14

Similar Documents

Publication Publication Date Title
CR20120027A (es) Polipeptidos y metodo de tratamiento
AR121002A2 (es) Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
EA201490825A1 (ru) Tdp-43-специфически связывающие молекулы
EA201792221A1 (ru) Антитела против сортилина и способы их применения
CR20150095A (es) Proteinas de unión a antígeno capaces de unirse a linfopoyetina estromática tímica
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
EA201492149A8 (ru) St2-антигенсвязывающие белки
EA201490677A1 (ru) Связывающие антиген cd27l белки
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
WO2009129538A3 (en) Human equivalent monoclonal antibodies engineered from nonhuman variable regions
GB201212940D0 (en) Antibodies to highly conserved targets
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
NZ594682A (en) Fully human antibodies specific to cadm1
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
PH12015500929A1 (en) Anti-campylobacter jejuni antibodies and uses therefor
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof